002688.SZ
金河生物
SZSE · Healthcare · C 制造业 · CN
CNY 5.18
+0.19%Year over year
Reported trailing growth
- Revenue
- +20.9%
- EBITDA
- —
- EBIT
- -44.8%
- EPS
- -61.9%
- Free cash flow
- -29.1%
- Operating cash flow
- -11.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +10.7%
- EBITDA
- +0.7%
- EBIT
- -29.5%
- Net income
- -28.6%
- EPS
- -28.6%
- Free cash flow
- +9.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026